Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALKBH2 | Q6NS38 | 2/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.36 |
| ▸ | ALKBH1 | Q13686 | 2/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17276611 | 0.87 | ROCK2 (0.44) | ROCK2SCDGPR119EGLN1ELANE | |
| SCHEMBL17633410 | 0.81 | ROCK2 (0.44) | ROCK2SCDGPR119ELANE | |
| SCHEMBL1843388 | 0.80 | ROCK2 (0.41) | ROCK2SCDL3MBTL1GPR119 | |
| SCHEMBL17648499 | 0.79 | ROCK2 (0.43) | ROCK2SCDGPR119ELANEPLAU | |
| SCHEMBL427252 | 0.79 | NOS1 (0.46) | ROCK2SCDGPR119ELANEPLAU | |
| SCHEMBL17633309 | 0.78 | ROCK2 (0.39) | ROCK2SCDL3MBTL1GPR119 | |
| SCHEMBL18083986 | 0.78 | ROCK2 (0.43) | ROCK2SCDGPR119ELANEPLAU | |
| SCHEMBL1206008 | 0.78 | ROCK2 (0.45) | ROCK2SCDGPR119ELANEPLAU | |
| SCHEMBL11901149 | 0.78 | ROCK2 (0.43) | ROCK2SCDGPR119ELANEPLAU | |
| SCHEMBL2549524 | 0.78 | ELANE (0.47) | ROCK2SCDELANEPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117003745-B | GLS1/HDAC double-target inhibitor and synthetic method and application thereof | 南京市第一医院 | 2024-06-07 | — | — | CN | claimed |
| CN-117003745-A | GLS1/HDAC double-target inhibitor and synthetic method and application thereof | 南京市第一医院 | 2023-11-07 | — | — | CN | claimed |
| EP-4499632-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20250026735-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2025-01-23 | — | — | US | disclosed |
| CN-119095839-A | Quinoline derivatives as modulators and related products of Mas-associated G protein receptor X2 | 伊赛恩特制药公司 | 2024-12-06 | — | — | CN | disclosed |
| US-12129244-B2 | Modulators of Mas-related G-protein receptor X2 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-12129243-B2 | Modulators of Mas-related G-protein receptor X2 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| CN-117003745-B | GLS1/HDAC double-target inhibitor and synthetic method and application thereof | 南京市第一医院 | 2024-06-07 | — | — | CN | disclosed |
| US-20240124414-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-04-18 | — | — | US | disclosed |
| US-20240124415-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-04-18 | — | — | US | disclosed |
| US-20240124416-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-04-18 | — | — | US | disclosed |
| EP-1318140-B9 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-05-21 | — | — | EP | disclosed |
| US-8198454-B2 | Amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-12 | — | — | US | disclosed |
| US-7855297-B2 | Amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20100041656-A1 | Novel amide derivatives and medicinal use thereof | NAKAMURA MITSUBARU | 2010-02-18 | — | — | US | disclosed |
| US-20060052365-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-09 | — | — | US | disclosed |
| EP-1539178-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040138223-A1 | Novel amide derivatives and medicinal use thereof ugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-15 | — | — | US | disclosed |
| WO-2004017911-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-1318140-A1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF UGS | Mitsubishi Pharma Corporation (JP) | 2003-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124415-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | ROCK2 995/4885SCD 4695/4885L3MBTL1 4132/4885 |
| US-12129244-B2 | Modulators of Mas-related G-protein receptor X2 and related products and methods | MRGPRX2, MRGPRX1, MRGPRX4 | ROCK2 995/4885SCD 4695/4885L3MBTL1 4132/4885 |
| US-20250026735-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | ROCK2 995/4885SCD 4695/4885L3MBTL1 4132/4885 |
| US-20240124416-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | ROCK2 995/4885SCD 4695/4885L3MBTL1 4132/4885 |
| US-20060052365-A1 | Protease inhibitors | CTSS, CTSE, CMA1 | ROCK2 2946/4885SCD 1270/4885L3MBTL1 3202/4885 |
| US-20100041656-A1 | Novel amide derivatives and medicinal use thereof | C5AR1, C5AR2, C3AR1 | ROCK2 1698/4885SCD 1765/4885L3MBTL1 1629/4885 |
| US-20240124414-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | ROCK2 995/4885SCD 4695/4885L3MBTL1 4132/4885 |
| US-12129243-B2 | Modulators of Mas-related G-protein receptor X2 and related products and methods | MRGPRX2, MRGPRX1, MRGPRX4 | ROCK2 995/4885SCD 4695/4885L3MBTL1 4132/4885 |
| US-20040138223-A1 | Novel amide derivatives and medicinal use thereof ugs | C5AR1, C5AR2, C1S | ROCK2 2647/4885SCD 1339/4885L3MBTL1 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.